Top 5 3rd Quarter Trades of Manning & Napier Group, LLC

Manning & Napier Group, LLC recently filed their 13F report for the third quarter of 2017, which ended on 2017-09-30.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

Manning & Napier (NYSE: MN) provides a broad range of investment solutions through separately managed accounts, mutual funds, and collective investment trust funds, as well as a variety of consultative services that complement its investment process.
Founded in 1970, the firm offers equity and fixed income portfolios as well as a range of blended asset portfolios, such as life cycle funds, that use a mix of stocks and bonds. It serves a diversified client base of high-net-worth individuals and institutions, including 401(k) plans, pension plans, Taft-Hartley plans, endowments and foundations. For many of these clients, the firm's relationship goes beyond investment management and includes customized solutions that address key issues and solve client-specific problems.

As of the latest 13F report, the guru’s equity portfolio contained 320 stocks valued at a total of $11.67Bil. The top holdings were MDT(3.52%), FB(3.26%), and NVS(3.23%).

According to GuruFocus data, these were Manning & Napier Group, LLC’s top five trades of the quarter.

Seagen Inc


The guru established a new position worth 2,574,895 shares in NAS:SGEN, giving the stock a 1.2% weight in the equity portfolio. Shares traded for an average price of $51.16 during the quarter.

On 07/12/2022, Seagen Inc traded for a price of $179 per share and a market cap of $32.95Bil. The stock has returned 19.40% over the past year.

GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 3 out of 10.

In terms of valuation, Seagen Inc has a price-book ratio of 10.96, a EV-to-Ebitda ratio of -50.69 and a price-sales ratio of 19.61.

The price-to-GF Value ratio is 1.15, earning the stock a GF Value rank of 3.

Incyte Corp


The guru established a new position worth 1,071,325 shares in NAS:INCY, giving the stock a 1.07% weight in the equity portfolio. Shares traded for an average price of $126.66 during the quarter.

On 07/12/2022, Incyte Corp traded for a price of $80.42 per share and a market cap of $17.81Bil. The stock has returned -1.32% over the past year.

GuruFocus gives the company a financial strength rating of 9 out of 10 and a profitability rating of 6 out of 10.

In terms of valuation, Incyte Corp has a price-earnings ratio of 19.14, a price-book ratio of 4.60, a EV-to-Ebitda ratio of 24.15 and a price-sales ratio of 5.74.

The price-to-GF Value ratio is 0.72, earning the stock a GF Value rank of 10.

DaVita Inc


During the quarter, Manning & Napier Advisors, Inc bought 0 shares of NYSE:DVA for a total holding of 3,588,450. The trade had a 0.96% impact on the equity portfolio. During the quarter, the stock traded for an average price of $60.27.

On 07/12/2022, DaVita Inc traded for a price of $84.5 per share and a market cap of $7.99Bil. The stock has returned -32.87% over the past year.

GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 9 out of 10.

In terms of valuation, DaVita Inc has a price-earnings ratio of 10.05, a price-book ratio of 9.52, a price-earnings-to-growth (PEG) ratio of 0.91, a EV-to-Ebitda ratio of 8.20 and a price-sales ratio of 0.78.

The price-to-GF Value ratio is 0.70, earning the stock a GF Value rank of 10.

Vertex Pharmaceuticals Inc


Manning & Napier Advisors, Inc reduced their investment in NAS:VRTX by 0 shares. The trade had a 0.83% impact on the equity portfolio. During the quarter, the stock traded for an average price of $150.14.

On 07/12/2022, Vertex Pharmaceuticals Inc traded for a price of $290.01 per share and a market cap of $74.17Bil. The stock has returned 48.40% over the past year.

GuruFocus gives the company a financial strength rating of 9 out of 10 and a profitability rating of 7 out of 10.

In terms of valuation, Vertex Pharmaceuticals Inc has a price-earnings ratio of 30.52, a price-book ratio of 6.80, a price-earnings-to-growth (PEG) ratio of 0.24, a EV-to-Ebitda ratio of 21.86 and a price-sales ratio of 9.46.

The price-to-GF Value ratio is 0.88, earning the stock a GF Value rank of 7.

Salesforce Inc


Manning & Napier Advisors, Inc reduced their investment in NYSE:CRM by 0 shares. The trade had a 0.79% impact on the equity portfolio. During the quarter, the stock traded for an average price of $91.97.

On 07/12/2022, Salesforce Inc traded for a price of $166.33 per share and a market cap of $165.50Bil. The stock has returned -28.85% over the past year.

GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 7 out of 10.

In terms of valuation, Salesforce Inc has a price-earnings ratio of 161.48, a price-book ratio of 2.81, a price-earnings-to-growth (PEG) ratio of 6.05, a EV-to-Ebitda ratio of 44.45 and a price-sales ratio of 5.90.

The price-to-GF Value ratio is 0.61, earning the stock a GF Value rank of 8.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.